Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

13 Canadian Crypto ETFs (Updated 2024)

Leigh Goehring: Gold's "Massive Bull Market" Just Starting; Uranium and Copper Outlook

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Top 4 Largest Lithium Reserves by Country (Updated 2024)

How Could Trump's US Election Win Affect the Gold Price?

Trending Press Releases

McDermitt PFS Demonstrates Multi-Decade Competitive Source of US Lithium Carbonate

OSISKO METALS EXPANDS LEADERSHIP TEAM AND ANNOUNCES C$100 MILLION BOUGHT DEAL FINANCING

Osisko Metals Announces Significant Increase in Mineral Resources at Gaspé Copper

Silver47 Drills 2.48m of 14.95 g/t Gold, 249.50 g/t Silver, 21.97% Zinc, 7.03% Lead, 0.42% Copper at Its Red Mountain Project, Alaska

SAGA Metals Announces Assay Results from North Wind Iron Ore Project

Jindalee Lithium

More Press Releases
Trending Companies

Silver47 Exploration

AGA:CC

Purpose Bitcoin ETF

BTCC:CA

Osisko Metals: Leading the Charge in Base Metal Investments

OM:CA

Syntheia

SYAI:CC
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Lithium Market Outlook

2024 AI Market Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Summit Therapeutics Inc.

NASDAQ:SMMT
Press Releases

Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection

Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Interactive Chart

×